Bio-Rad Laboratories (BIO) Stock Overview
Manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BIO Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Bio-Rad Laboratories, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$303.82 |
| 52 Week High | US$387.99 |
| 52 Week Low | US$211.43 |
| Beta | 0.91 |
| 1 Month Change | 15.00% |
| 3 Month Change | 35.77% |
| 1 Year Change | -3.53% |
| 3 Year Change | -38.66% |
| 5 Year Change | -39.09% |
| Change since IPO | 11,788.61% |
Recent News & Updates
Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
Aug 07Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results
Aug 03
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Jul 14Recent updates
Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
Aug 07Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results
Aug 03We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Jul 14
Acquisition And Droplet Digital PCR Will Advance Oncology Diagnostics
Bio-Rad's efforts in digital PCR technology and strategic acquisitions aim to expand applications and bolster revenue through oncology diagnostics and rare mutation detection.Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Apr 10Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
Mar 18Some Confidence Is Lacking In Bio-Rad Laboratories, Inc. (NYSE:BIO) As Shares Slide 28%
Feb 28Is There An Opportunity With Bio-Rad Laboratories, Inc.'s (NYSE:BIO) 39% Undervaluation?
Feb 18Bio-Rad: Uncertainties And Conservatism Continue To Hold Stock Back From Its Full Potential
Jan 29Getting In Cheap On Bio-Rad Laboratories, Inc. (NYSE:BIO) Is Unlikely
Jan 06Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Dec 16Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis
Nov 25Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?
Nov 25A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Nov 04Bio-Rad Laboratories: Overvalued Given Current Growth Prospects
Sep 23We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Sep 08Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar
Jul 14Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Apr 14Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance
Oct 25Bio-Rad: A Cash Flow Returns On Investments Analysis
Aug 10Bio-Rad Labs reports Q4 2022 results
Feb 16Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
Jan 04Shareholder Returns
| BIO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 6.4% | 1.8% | 0.5% |
| 1Y | -3.5% | -19.0% | 15.7% |
Return vs Industry: BIO exceeded the US Life Sciences industry which returned -19% over the past year.
Return vs Market: BIO underperformed the US Market which returned 15.7% over the past year.
Price Volatility
| BIO volatility | |
|---|---|
| BIO Average Weekly Movement | 6.7% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BIO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 7,700 | Norman Schwartz | www.bio-rad.com |
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications.
Bio-Rad Laboratories, Inc. Fundamentals Summary
| BIO fundamental statistics | |
|---|---|
| Market cap | US$7.93b |
| Earnings (TTM) | US$319.20m |
| Revenue (TTM) | US$2.55b |
Is BIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO income statement (TTM) | |
|---|---|
| Revenue | US$2.55b |
| Cost of Revenue | US$1.20b |
| Gross Profit | US$1.35b |
| Other Expenses | US$1.03b |
| Earnings | US$319.20m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 11.79 |
| Gross Margin | 52.96% |
| Net Profit Margin | 12.50% |
| Debt/Equity Ratio | 16.7% |
How did BIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/24 14:29 |
| End of Day Share Price | 2025/08/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bio-Rad Laboratories, Inc. is covered by 25 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Jon Wood | BofA Global Research |
| Yuan Zhi | B. Riley Securities, Inc. |